# Melatonin Supplementation for Cancer-related Fatigue in Patients Receiving Radiotherapy

> **NCT02332928** · PHASE3 · TERMINATED · sponsor: **Virginia Commonwealth University** · enrollment: 80 (actual)

## Conditions studied

- Breast Cancer - Female

## Interventions

- **DRUG:** Melatonin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02332928
- **Lead sponsor:** Virginia Commonwealth University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-03-25
- **Primary completion:** 2021-06-02
- **Final completion:** 2021-06-02
- **Target enrollment:** 80 (ACTUAL)
- **Why stopped:** Lack of efficacy
- **Last updated:** 2023-03-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02332928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02332928, "Melatonin Supplementation for Cancer-related Fatigue in Patients Receiving Radiotherapy". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT02332928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*